Patient benefit-risk preferences for targeted agents in the treatment of renal cell carcinoma.
about
Pazopanib in the treatment of advanced renal cell carcinomaPatients' Preferences for Outcome, Process and Cost Attributes in Cancer Treatment: A Systematic Review of Discrete Choice Experiments.Improving current immunoglobulin therapy for patients with primary immunodeficiency: quality of life and views on treatmentBudget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain.Patient Benefit-Risk Tradeoffs for Radioactive Iodine-Refractory Differentiated Thyroid Cancer TreatmentsPatient, Caregiver, and Nurse Preferences for Treatments for Bone Metastases from Solid Tumors.Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma.Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer.Physician and patient benefit-risk preferences from two randomized long-acting injectable antipsychotic trials.Quantifying benefit-risk preferences for medical interventions: an overview of a growing empirical literature.Measuring trade-offs in nephrology: a systematic review of discrete choice experiments and conjoint analysis studies.Validation of a short questionnaire to measure symptoms and functional limitations associated with hand-foot syndrome and mucositis in patients with metastatic renal cell carcinoma.Preferences and Stated Adherence for Antibiotic Treatment of Cystic Fibrosis Pseudomonas Infections.Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.The effect of information on preferences for treatments of metastatic renal cell carcinoma.Patient preferences for treatments to delay bone metastases.Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial.Physicians' preferences for bone metastases treatments in France, Germany and the United Kingdom.
P2860
Q26770413-1B0E5EF2-0779-4A58-8CC9-035DA47621E7Q30235008-71924B56-D663-44B5-9FEE-1FD606E886E2Q33583520-5149B863-4FDB-4AB8-8E97-1988E32D8747Q34978199-92A6C1AE-B79B-463E-BC01-55D799B1557AQ36366960-A695E8AD-61A8-4914-A815-96F07576D193Q37048841-CC8BC55B-BD5F-4F5E-A5D0-FD2BE5F62843Q37201213-66A8B307-B447-462C-8F19-348E5DC5DDE4Q37374245-E860BD0D-F705-4EAF-9DA2-4E3469E0791CQ37376779-D0706EAA-903C-4439-B841-4FA1193755A7Q38103514-0E7BD41A-2C2E-40F5-A851-1B6F9B7A2EB2Q39118145-CBACBE57-EAB4-4A03-B697-FF3B9170B9A5Q40442210-200217FE-AB78-43C8-8512-A77829C6185DQ41119815-4DE62164-EE42-43FF-BDAF-35DFDFB6CD43Q45048423-E74E841F-0C81-46F0-B5AB-27C7509EA1CDQ53136887-291DDECB-E331-445D-B73E-F6E28D778566Q53264477-206810EC-D2CE-4A5B-BB15-144FBA3D6B0DQ55251012-09ADAD1A-40CA-42B2-BC98-D4EA26A5A182Q55518625-3B1A22B9-885B-49C7-B8F0-5C02FC5B6DCB
P2860
Patient benefit-risk preferences for targeted agents in the treatment of renal cell carcinoma.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Patient benefit-risk preferenc ...... tment of renal cell carcinoma.
@en
Patient benefit-risk preferenc ...... tment of renal cell carcinoma.
@nl
type
label
Patient benefit-risk preferenc ...... tment of renal cell carcinoma.
@en
Patient benefit-risk preferenc ...... tment of renal cell carcinoma.
@nl
prefLabel
Patient benefit-risk preferenc ...... tment of renal cell carcinoma.
@en
Patient benefit-risk preferenc ...... tment of renal cell carcinoma.
@nl
P2093
P2860
P1433
P1476
Patient benefit-risk preferenc ...... tment of renal cell carcinoma.
@en
P2093
A Brett Hauber
Ateesha F Mohamed
Maureen P Neary
P2860
P304
P356
10.2165/11593370-000000000-00000
P577
2011-11-01T00:00:00Z
P5875
P6179
1010605261